Elastography Imaging Market Forecast: 7.2% CAGR to Push Value to US$7.5 Billion by 2032

The global elastography imaging market is positioned for steady expansion, projected to grow from US$4.6 billion in 2025 to US$7.5 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.2%. This growth trajectory underscores the industry's transition from specialized radiological applications to mainstream diagnostic use in hepatology, oncology, and musculoskeletal medicine. The rising burden of chronic diseases and increasing clinical preference for non-invasive, real-time diagnostic solutions are key growth enablers. Historically, the market expanded at a CAGR of 6.8% from 2019 to 2024, signaling a consistent upward trend bolstered by technological advancements and expanded reimbursement coverage in major healthcare economies.

Ultrasound elastography remains the dominant modality, representing approximately 70.1% of total market share in 2025, driven by its portability, affordability, and ability to provide real-time stiffness mapping. Magnetic Resonance Elastography (MRE), however, is gaining traction in clinical trials and research applications due to its superior reproducibility and comprehensive organ coverage. From a clinical standpoint, general imaging applications account for 33.8% of global revenue, with widespread use in liver, thyroid, and musculoskeletal assessments.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35570

Key Industry Highlights

North America continues to lead the global market, capturing nearly 35.7% of global share in 2025, primarily due to favorable reimbursement policies and early integration of elastography into routine hepatology and breast imaging workflows. Europe is the fastest-growing region, supported by government-backed cancer screening programs and public health initiatives promoting early disease detection. A recent 2025 study published in the Egyptian Journal of Radiology and Nuclear Medicine reinforced elastography's expanding clinical relevance, demonstrating the effectiveness of shear-wave elastography in monitoring liver iron overload in pediatric patients with β-thalassemia major, offering a valuable alternative to MRI in resource-limited settings.

Market Dynamics

Driver - Rising Burden of Chronic Liver Disease and Breast Cancer Spurs Demand

The escalating prevalence of chronic liver disease, particularly conditions like hepatitis B, hepatitis C, and Non-Alcoholic Fatty Liver Disease (NAFLD), has significantly increased the demand for elastography imaging. Hospitals in Europe have reported up to a 40% reduction in biopsy rates following the adoption of elastography for fibrosis staging. This aligns with a global shift toward non-invasive diagnostic approaches that reduce patient discomfort and procedural risks. Additionally, the global burden of breast cancer continues to rise, with the WHO estimating over 670,000 deaths in 2022, heightening the need for accurate, cost-effective diagnostic tools. Elastography's ability to differentiate benign from malignant lesions through stiffness analysis makes it an indispensable adjunct to mammography, particularly in dense breast tissue where traditional imaging is less effective.

Restraint - Technical Challenges in Obese Patients Limit Reliability

Despite its clinical promise, elastography imaging faces notable limitations in obese patients due to attenuation of ultrasound signals by adipose tissue. Inadequate signal penetration compromises stiffness accuracy, particularly in liver assessments. A 2023 multicenter study published in Hepatology Communications revealed that liver stiffness measurements failed in approximately 15% of obese subjects, prompting repeated examinations or biopsy confirmation. Similar challenges persist in breast elastography, where large breast size or high-density tissue can distort compression-based measurements. Manufacturers are actively developing AI-based correction algorithms and specialized probes to improve signal quality, but the technology's reliability remains inconsistent in certain patient populations.

Opportunity - Multi-Modality Platforms Strengthen Oncology Diagnostics

The emergence of multi-modality elastography systems represents a significant opportunity for industry growth. By integrating ultrasound and MR elastography, clinicians can achieve greater diagnostic accuracy through cross-validation of tissue stiffness metrics. These hybrid systems are proving particularly valuable in oncology, where distinguishing benign from malignant lesions requires complementary imaging data. The fusion of modalities also aligns with the broader trend toward personalized medicine, enabling continuous disease monitoring and improved treatment planning. The growing clinical adoption of multi-modality systems is expected to accelerate R&D investments, further strengthening the market outlook through 2032.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/elastography-imaging-market.asp

Category-wise Analysis

Modality Insights

The ultrasound elastography segment leads the global market, supported by widespread clinical adoption and cost-efficiency. The ability to retrofit existing ultrasound machines with elastography software modules significantly reduces capital expenditure, fostering adoption in hospitals and diagnostic centers. This modality's real-time feedback and ease of use make it the preferred choice in liver disease assessment, breast imaging, and musculoskeletal applications.
Magnetic Resonance Elastography (MRE), though representing a smaller market share, is gaining clinical relevance due to its reproducibility and capability to map entire organ stiffness. Its growing use in MASLD and MASH clinical trials provides consistent endpoints for regulatory submissions, giving it a strategic advantage in pharmaceutical research.

Application Insights

Among application categories, general imaging leads the market due to the broad clinical applicability of elastography across various organ systems. Multi-organ capabilities enable hospitals to maximize return on investment, as the same device can be used for liver, thyroid, prostate, and soft tissue evaluations. Breast imaging is the second-largest segment, driven by the global push for early detection and diagnosis of breast cancer in younger women. In Asia Pacific and parts of Europe, elastography is increasingly used as a complementary tool to mammography in populations with high breast density. Hospitals in Japan and India, for example, have integrated elastography into national screening protocols for women under 40, expanding its role in preventive oncology.

Regional Insights

North America

North America dominates the global elastography imaging landscape, accounting for over one-third of total market share in 2025. The region benefits from structured reimbursement frameworks, particularly through the U.S. Centers for Medicare & Medicaid Services (CMS). Specific CPT codes-such as 76391 for MR elastography-facilitate standardized billing, driving clinical integration in hepatology and radiology practices. The U.S. market's growth is supported by rising awareness of fatty liver diseases and ongoing expansion into MASLD and alcohol-related liver disease diagnostics. Major hospital networks are embedding elastography into multidisciplinary care pathways, cementing its role in early disease detection and longitudinal monitoring.

Europe

Europe is projected to experience the fastest CAGR during the forecast period, propelled by national health initiatives and updated clinical guidelines. France has positioned transient elastography as a cornerstone tool for chronic liver disease management, while Germany and the U.K. favor shear-wave elastography for its cost-efficiency and adaptability to multipurpose ultrasound systems. The European Association for the Study of the Liver (EASL)'s 2024 guidelines endorsing elastography for MASLD and MASH staging have accelerated adoption in hospitals across Spain and Italy. Furthermore, ongoing public health investments in cancer screening programs are expanding the clinical footprint of elastography beyond hepatology.

Asia Pacific

Asia Pacific is an emerging growth frontier, with adoption led by China, Japan, and India. China's domestic manufacturers are catalyzing market expansion through competitively priced elastography platforms that match global performance benchmarks, enabling access beyond tertiary centers. Japan remains a high-value market, driven by advanced imaging integration in university hospitals and research centers conducting fibrosis and oncology trials. India's urban healthcare providers are increasingly incorporating elastography into liver and breast imaging workflows, though rural penetration remains limited. Collectively, these trends position Asia Pacific as a pivotal region for volume-driven growth over the next decade.

Competitive Landscape

The global elastography imaging market features a competitive mix of diversified imaging conglomerates and specialized device manufacturers. Leading players such as GE Healthcare, Siemens AG, Canon Medical Systems, Philips Healthcare, and Hitachi Ltd. dominate the premium segment, leveraging extensive R&D capabilities and AI-driven imaging software to enhance diagnostic accuracy. FUJIFILM, Mindray, Esaote, and Samsung Medison continue to expand their mid-tier portfolios, emphasizing compact, portable systems suitable for outpatient and field applications.

Strategic collaborations, mergers, and product launches characterize the industry's competitive dynamics. The integration of AI and machine learning is becoming a critical differentiator, enabling vendors to enhance image reconstruction, automate fibrosis quantification, and streamline workflow efficiency. Smaller companies are focusing on niche specializations, particularly in hepatology, where portable elastography solutions are gaining traction.

Recent Developments

In August 2025, Sonic Incytes Medical Corp received FDA 510(k) clearance for Velacur ONE, a point-of-care ultrasound elastography system designed for enhanced portability and intuitive operation, marking a milestone in decentralized diagnostic imaging. In April 2025, Royal Philips introduced the Elevate Platform for its EPIQ Elite ultrasound line, integrating proactive system monitoring and remote consultation capabilities, facilitating remote diagnostics and predictive maintenance. Additionally, leading manufacturers have expanded partnerships with academic institutions to validate new stiffness algorithms and AI-based image enhancement technologies.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35570

Market Segmentation

By Modality

Ultrasound
Magnetic Resonance

By Application

General Imaging
Hepatology
Breast
Cardiology
Nephrology
Orthopedic and Musculoskeletal

By End-user

Hospitals
Imaging Centers
Others

By Region

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Future Outlook

Looking ahead, the elastography imaging market is expected to enter a phase of accelerated innovation and clinical standardization. The ongoing convergence of ultrasound and MR technologies, combined with AI-powered analytics, will redefine diagnostic precision across hepatology and oncology. Emerging economies will increasingly adopt elastography as a first-line diagnostic modality, aided by cost reductions and government-sponsored screening initiatives.

From a long-term perspective, advancements in probe sensitivity, imaging algorithms, and hybrid diagnostic systems will expand the clinical reach of elastography beyond traditional use cases. By 2032, as the global healthcare ecosystem shifts toward preventive and precision medicine, elastography imaging is projected to become a mainstay diagnostic tool, valued for its ability to deliver rapid, non-invasive, and quantifiable insights into tissue pathology.

Key Players in the Global Elastography Imaging Market

Canon Medical Systems Corporation
FUJIFILM Corporation
Esaote SpA
Mindray Bio-Medical Electronics Co., Ltd.
Koninklijke Philips N.V.
Hitachi, Ltd.
GE Healthcare
Toshiba America Medical Systems, Inc.
Siemens AG
Samsung Medison Co., Ltd.

In summary, the global elastography imaging market is set for robust expansion, underpinned by rising clinical adoption, favorable reimbursement frameworks, and rapid technological evolution. As healthcare systems worldwide pivot toward early diagnosis and minimally invasive care, elastography imaging will play an increasingly critical role in modern diagnostics, reshaping clinical pathways across hepatology, oncology, and musculoskeletal medicine.

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.